Brought to you by:
Risk of venous stent migration ‘rare’ but probably ‘underreported,’ systematic review finds
Stent migration following treatment of acute iliofemoral thrombus or venous obstruction is “rare but may be underreported,” with the majority of reported cases being shorter and smaller diameter stents. This is the main concluding finding of a systematic review published…
Office-based laboratory setting proves ‘safe’ for iliac vein stenting
A retrospective study of 1,223 iliac vein cases performed in three office-based laboratories (OBLs) demonstrated a major complication rate of 0.41%, suggesting these procedures are safe and well-tolerated in this setting, the authors say. According to corresponding researcher Levan Sulakvelidze,…
Thrombolex: Investigational RESCUE trial yields ‘exciting’ interim data
The prespecified interim analysis of the first 62 evaluable pulmonary embolism (PE) patients enrolled in the investigational RESCUE trial produced positive results, Thrombolex has announced. RESCUE is a prospective multicenter, single-arm pivotal trial evaluating patient outcomes after treatment of acute…
Europe: ESVS publishes 2022 guidelines on management of chronic venous disease of the lower limb
The European Society for Vascular Surgery (ESVS) has released 2022 clinical practice guidelines on the management of chronic venous disease (CVD) of the lower limb to update its 2015 recommendations. The document, authored by Marianne De Maeseneer, MD, a venous…
VIVID study on Duo venous stent system now fully enrolled, Vesper Medical announces
Vesper Medical recently announced the completion of enrollment in its pivotal study—VIVID (Venous stent for the iliofemoral vein investigational clinical trial using the Vesper Duo venous stent system). VIVID enrolled its 160th patient earlier this month, marking completion of enrollment in the trial.…
FDA approves two pediatric venous thromboembolism indications for rivaroxaban
The Food and Drug Administration (FDA) has approved two pediatric indications for Xarelto (rivaroxaban): the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of…
Venous disease: SVS DEI Committee seeks survey participants
The Society for Vascular Surgery (SVS) Diversity, Equity and Inclusion (DEI) Committee is calling on vascular surgeons to complete a survey focused on patterns of practice in venous disease. Responses are due by Friday, Dec. 31. The committee seeks respondents…
Study: Early thrombosis after iliac stenting for venous outflow occlusion is related to disease severity, anticoagulation type
Fewer than 10 days of low-molecular-weight heparin (LMWH) after stenting for extensive iliofemoral venous occlusion prior to transition to oral anticoagulation reduces early thrombosis, according to a multicenter study. Thrombosis following iliofemoral venous stenting is frustrating to both the patient…
Three-year VIVO results back ‘continued safety and effectiveness’ of Zilver Vena venous stent
Three-year results of the VIVO clinical study support the continued safety and effectiveness of the Zilver Vena venous stent (Cook Medical) in the treatment of symptomatic iliofemoral venous outflow obstruction, attendees at the Vascular Interventional Advances (VIVA) 2021 (Oct. 5–7) in Las Vegas.…
Registry data show greater clot chronicity on post-procedure inspection than initially predicted
Nearly half of patients deemed pre-procedurally to be suffering an acute case of deep vein thrombosis (DVT) turned out to have a “much more” chronic classification of the condition following intraoperative imaging and thrombus inspection post-procedure, an interim analysis from…